-
公开(公告)号：US08409568B2
公开(公告)日：2013-04-02
申请号：US12837208
申请日：2010-07-15
申请人： Changshou Gao , Herren Wu
发明人： Changshou Gao , Herren Wu
IPC分类号： C07K16/00 , G01N33/563 , A61K39/395
CPC分类号： C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2842 , C07K16/2848 , C07K16/2866 , C07K2317/21 , C07K2317/622 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2319/03 , C07K2319/035 , C07K2319/30 , C12N15/1037
摘要： The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
摘要翻译： 本发明涉及编码当在细胞中表达时在细胞膜上显示的抗体文库或抗体片段的病毒载体。 本发明提供了包含病毒载体核酸的细胞和筛选具有所需特征的抗体或抗体片段的文库的方法。
-
公开(公告)号：US08193329B2
公开(公告)日：2012-06-05
申请号：US13007061
申请日：2011-01-14
申请人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
发明人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译： 本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途 补体激活。 这些抗体可用于疾病的诊断，预防和治疗。
-
公开(公告)号：US20120135006A1
公开(公告)日：2012-05-31
申请号：US13279592
申请日：2011-10-24
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1027 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
摘要翻译： 公开了具有1010M-1甚至1011M-1范围内的结合亲和力的超高亲和力抗体。 此类抗体包括具有新型高亲和力互补决定区（CDR）的抗体，特别是具有来自人或小鼠的骨架和恒定区的抗体。 还公开了制备和筛选这些抗体的方法，以及使用它们来预防和/或治疗疾病，特别是病毒诱导的疾病的方法。
-
公开(公告)号：US08187604B2
公开(公告)日：2012-05-29
申请号：US13007142
申请日：2011-01-14
申请人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
发明人： Ling-Ling An , Sek Chung Fung , Robert F. Kelley , Henry B. Lowman , Sanjaya Singh , Herren Wu
IPC分类号： A61K39/395 , C07K16/18 , C07K16/36
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/50 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
摘要翻译： 本发明涉及人源化抗人因子D单克隆抗体，其核酸和氨基酸序列，携带这些抗体的细胞和载体及其在制备用于治疗与过度或不受控制的疾病和病症的组合物和药物中的用途 补体激活。 这些抗体可用于疾病的诊断，预防和治疗。
-
5.发明申请METHODS OF ADMINISTERING / DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT 审中-公开用于预防和治疗的抗RSV抗体的方法公开(公告)号：US20120070447A1
公开(公告)日：2012-03-22
申请号：US12906948
申请日：2010-10-18
申请人： JAMES F. YOUNG , SCOTT KOENIG , LESLIE S. JOHNSON , WILLIAM D. HUSE , JEFFREY D. WATKINS , HERREN WU
发明人： JAMES F. YOUNG , SCOTT KOENIG , LESLIE S. JOHNSON , WILLIAM D. HUSE , JEFFREY D. WATKINS , HERREN WU
IPC分类号： A61K39/42 , C12N15/13 , C07K16/46 , A61P31/14 , C12N1/21 , C12N5/10 , C12P21/00 , C12Q1/70 , C12N1/19 , C07K16/10 , C12N15/63
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection
摘要翻译： 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法
-
公开(公告)号：US20120046450A1
公开(公告)日：2012-02-23
申请号：US13190199
申请日：2011-07-25
CPC分类号： C07K16/18 , C07K16/00 , C07K16/2866 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。
-
公开(公告)号：US20100239574A1
公开(公告)日：2010-09-23
申请号：US12707527
申请日：2010-02-17
CPC分类号： C07K16/1027 , A61K2039/505 , C07K16/00 , C07K2317/567
摘要： High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
摘要翻译： 公开了具有高动力学关联速率常数和任选的高亲和力的高效力抗体，包括其免疫活性片段，以及产生此类抗体的方法。 本文公开的高效抗体是中和或非中和型，并且对由微生物，特别是病毒以及存在于癌细胞和各种类型毒素上的抗原位点以及毒素产物显示的抗原具有特异性。 还描述了用于产生高效中和抗体并增加已经存在的中和抗体的效力的方法。 公开了在预防和/或治疗疾病，特别是由病毒引起或引起的疾病中使用所述抗体的方法。
-
公开(公告)号：US20100216975A1
公开(公告)日：2010-08-26
申请号：US12697597
申请日：2010-02-01
CPC分类号： C07K16/005 , C07H21/04 , C07K16/2863 , C07K16/40 , C07K16/464 , C07K2317/55 , C07K2317/92 , C12N15/1027
摘要： The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.
摘要翻译： 本发明涉及重新设计或重塑抗体以降低抗体免疫原性的方法，同时保持针对抗原的抗体的免疫特异性。 特别地，本发明提供了通过合成包含来自框架区域的子库的框架区域融合的供体抗体的互补决定区（CDR）的组合文库的组合文库来产生针对抗原免疫特异性的抗体的方法。 本发明还提供了生产改良的人源化抗体的方法。 本发明还提供通过本发明的方法制备的抗体。
-
9.发明申请Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed Mutagenesis 审中-公开通过定点突变增加哺乳动物细胞中重组抗体的产生公开(公告)号：US20100145028A1
公开(公告)日：2010-06-10
申请号：US12706264
申请日：2010-02-16
CPC分类号： C07K16/2866 , C07K16/00 , C07K16/2848 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/92 , C12N2510/02
摘要： The present invention relates to a reliable, reproducible method for improving the producibility of an antibody. More specifically, this invention provides a method for modifying the heavy chain of an antibody to improve its producibility in eukaryotic cells. Additionally, the method of the invention may improve both antibody producibility and one or more antigen binding characteristics. The invention further provides modified antibodies which are better produced and which have either no change in their antigen binding characteristics or exhibit improved antigen binding characteristics.
摘要翻译： 本发明涉及提高抗体可生产性的可靠，可重现的方法。 更具体地，本发明提供了修饰抗体重链以改善其在真核细胞中的可生产性的方法。 此外，本发明的方法可以改善抗体可产生性和一种或多种抗原结合特征。 本发明还提供了更好地产生并且其抗原结合特征没有变化或表现出改善的抗原结合特征的修饰抗体。
-
10.发明申请METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT 失效用于预防和治疗的抗RSV抗体的方法公开(公告)号：US20100028948A1
公开(公告)日：2010-02-04
申请号：US12476183
申请日：2009-06-01
申请人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
发明人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
摘要翻译： 本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。 本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为 所述抗体或抗体片段在所述人受试者中实现。 本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定 所述抗体或抗体片段的血清滴度在所述人受试者中实现。 本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
111 条记录 (耗时 0.057 秒)
